Antibody to osteoclast alphavbeta3 ntegrin
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 26, 1996
Issued Date -
N/A
app pub date -
Sep 30, 1994
filing date -
Apr 3, 1992
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Hybridoma cell line, ATCC HB 11029, which produces murine monoclonal antibody, 10C4.1.3 which specifically binds to alphavbeta3 integrin on human osteoclasts, and is capable of blocking binding of alphavbeta3 integrin to fibrinogen or to vitronectin. The antibody is useful for detecting alphavbeta3 integrin on cells in histological and diagnostic assays, and to treat disease conditions that are characterized by excessive bone resorption.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully